Nov 8, 2026 · New England Journal of Medicine
WEIGHT-LOSS DRUG RETATRUTIDE CUTS KNEE OSTEOARTHRITIS PAIN IN TWO PHASE 3 TRIALS
The experimental once-weekly injection retatrutide cut knee osteoarthritis pain by at least half in about two-thirds of trial participants with obesity, compared with 38 percent on placebo, in two phase 3 trials published November 8 in the New England Journal of Medicine. In the TRIUMPH-4 trial of 445 adults, pain scores fell 3.96 points on the 9 mg dose and 3.74 on 12 mg, against 2.12 on placebo, while body weight fell 20 to 24 percent. The drug is not approved by the FDA, patients who needed a knee replacement were excluded, and the trials were not designed to show whether it slows arthritis or reduces the need for surgery.